ADC Therapeutics Overview

  • Founded
  • 2011
Founded
  • Status
  • Public
  • Employees
  • 149
Employees
  • Stock Symbol
  • ADCT
Stock Symbol
  • Share Price
  • $26.59
  • (As of Friday Closing)

ADC Therapeutics General Information

Description

ADC Therapeutics SA is a United States-based clinical-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's product candidate includes ADCT-402, ADCT-301, ADCT-602, and ADCT-601.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Biotechnology
Stock Exchange
NYS
Primary Office
  • Biopole
  • Route de la Corniche 3B
  • 1066 Epalinges
  • Switzerland
+41 021 000 00 00
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

ADC Therapeutics Stock Performance

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$26.59 $28.48 $25.11 - $56.59 $2.04B 76.7M 232K -$3.89

ADC Therapeutics Financials Summary

In Thousands,
USD
TTM 30-Sep-2020 FY 2019 31-Dec-2019 FY 2018 31-Dec-2018 FY 2017 31-Dec-2017
EV 2,131,782
Revenue 0 2,340 1,140 1,803
EBITDA (221,484) (116,353) (124,988) (90,504)
Net Income (225,646) (116,484) (123,096) (89,862)
Total Assets 521,526 137,682 150,558 271,949
Total Debt 113,276 5,031 0 0
Public Fundamental Data provided by Morningstar, Inc. disclaimer

ADC Therapeutics Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore ADC Therapeutics‘s full profile, request access.

Request a free trial

ADC Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is available in the PitchBook Platform. To explore ADC Therapeutics‘s full profile, request access.

Request a free trial

ADC Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
ADC Therapeutics SA is a United States-based clinical-stage oncology-focused biotechnology company. It is involved in th
Drug Discovery
Epalinges, Switzerland
149 As of 2020
00.000
00000000 00.000

0000000

a pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt molli
0000 000000000
Beijing, China
0000 As of 0000
00.000
00000000000 00.000

0000000

derit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupida
0000 000000000
Bothell, WA
0000 As of 0000
00.000
000000000 00.000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

ADC Therapeutics Competitors (58)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
BeiGene Formerly PE-Backed Beijing, China 0000 00.000 00000000000 00.000
0000000 00000000 Formerly VC-backed Bothell, WA 0000 00.000 000000000 00.000
00000 000000000000 Formerly VC-backed London, United Kingdom 00 00000 000000000 00000
00000 000000000000 Formerly PE-Backed Singapore, Singapore 00 00000 000000000 00000
000000000 00000000 Formerly VC-backed San Francisco, CA 000 00000 000000&0 00000
You’re viewing 5 of 58 competitors. Get the full list »

ADC Therapeutics Executive Team (17)

Name Title Board Seat Contact Info
Chris Martin Ph.D Chief Executive Officer & Board Member
Jennifer Creel Chief Financial Officer
Susan Romanus Chief Compliance Officer
Stéphane Henchoz Director, Finance
Jennifer Herron Chief Commercial Officer
You’re viewing 5 of 17 executive team members. Get the full list »

ADC Therapeutics Board Members (13)

Name Representing Role Since
Barrie Ward Ph.D Self Board Member 000 0000
Chris Martin Ph.D ADC Therapeutics Chief Executive Officer & Board Member 000 0000
Jacques Theurillat Self Board Member 000 0000
Michael Forer ADC Therapeutics Vice Chairman 000 0000
Peter Corr Ph.D Auven Therapeutics Chairman 000 0000
You’re viewing 5 of 13 board members. Get the full list »

ADC Therapeutics Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

ADC Therapeutics Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore ADC Therapeutics‘s full profile, request access.

Request a free trial